Paul Hopper has over 25 years of experience in international public company markets primarily in the biotechnology & healthcare sectors, with a particular focus on cancer vaccines where he has been closely involved in clinical trials from Phase 1 to Phase 3 studies. Focussed on startup and rapid growth companies, he has served as founder, chair, non-executive director and chief executive of more than fourteen companies in the US, Australia and Asia. His experience covers extensive fund raising in Australia, Asia, US and Europe; and has deep experience in corporate governance, risk and strategy. Mr Hopper also has extensive experience providing corporate advice and guidance, financial analysis and management of companies of different sizes and financial circumstances. He has been executive director of Prescient Therapeutics since May 2014 and moved to a non-executive role in July 2017.